AM-Pharma

Private

Bunnik, UtrechtHealthcare & Life Scienceshttps://www.am-pharma.com

Last Round

Debt

Mar 31, 2020

Total Funding Raised

$322.1M

Company Overview

AM-Pharma is a biotechnology company focused on developing alkaline phosphatase biologic therapies to treat acute kidney injury and other related diseases, offering innovative treatments aimed at enhancing patient quality of life.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

ilofotase alfarecombinant human alkaline phosphatasecardiac surgery-associated renal damageCSA-RDacute kidney injuryAKIhypophosphatasiaHPPenzyme replacement therapykidney protectionkidney disease treatmentrare disease therapyclinical-stage biopharmadrug licensingbiologic drugFDA fast-tracksepsis treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AM-Pharma Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AM-Pharma Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Debt	Mar 31, 2020
Series F	Jul 16, 2019
Corporate Funding	May 11, 2015
Series D Extension	Sep 11, 2014
Series D	Sep 13, 2011
Debt	Mar 19, 2009

View all Funding Rounds

Key People

Founding team and executive leadership

Juliane Bernholz

Chief Executive Officer

Executive Team

AM-Pharma Investors

Notable investors and investment history

Investor	Rounds
Forbion Capital Partners	Series C, Series F, Series D
EQT Life Sciences	Series F
Idinvest Partners	Series D Extension, Series F, Series D
BB Biotech	Series D Extension, Series D
Andera Partners	Debt, Series F
Ysios Capital	Series D Extension, Series F, Debt
Blue Owl Capital	Debt

View all Investors

AM-Pharma Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

AM-Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AM-Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBunnik, Utrecht

Employee Range31

Year Founded2001

Last FundingMar 31, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.